Cellectis SA (CLLS) has released an update.
Cellectis, a biotech firm focused on gene-editing for cancer treatments, reported successful shareholder voting outcomes with nearly half of its stock represented, and all but one management-supported resolutions passed. The meeting’s detailed voting results are accessible on the company’s website. Cellectis continues to develop its innovative CAR-T cell therapies and gene-editing technologies to address critical medical needs.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
